RANK-L Inhibitors Drug-Drug Interaction Table: Complete Prescriber Reference

What Is the RANK-L Inhibitor Drug Class?

RANK-L inhibitors are biologics that bind RANK ligand (receptor activator of nuclear factor kappa-B ligand), preventing it from activating its receptor (RANK) on osteoclast precursors. The result is reduced osteoclast formation, function, and survival. Denosumab is the only FDA-approved RANK-L inhibitor as of 2025, marketed in two distinct formulations that differ by indication, dose, and frequency.

Mechanism at the Cellular Level

RANK ligand is produced by osteoblasts, stromal cells, and activated T cells. When RANK-L binds RANK on osteoclast precursors, it triggers osteoclastogenesis through NF-kB and other downstream pathways. Denosumab mimics the endogenous decoy receptor osteoprotegerin (OPG) by binding RANK-L with high affinity (K_d approximately 3 × 10^-12 M), blocking this interaction entirely. Bone resorption markers such as serum CTX-1 fall within 1 to 3 days of the first injection.

FDA-Approved Agents in the Class

| Brand | Generic | Approved Indications | Dose | |-------|---------|----------------------|------| | Prolia | denosumab 60 mg/mL | Postmenopausal osteoporosis; male osteoporosis; glucocorticoid-induced osteoporosis; bone loss with hormone-ablation therapy | 60 mg SC every 6 months | | Xgeva | denosumab 70 mg/mL | Bone metastases (solid tumors); multiple myeloma bone disease; giant cell tumor of bone; hypercalcemia of malignancy | 120 mg SC every 4 weeks |

No biosimilar to denosumab had received FDA approval as of the time of this writing, though several are in late-stage regulatory review.

Distinction from Bisphosphonates

Bisphosphonates (alendronate, zoledronic acid) adsorb into bone mineral and inhibit osteoclasts through farnesyl pyrophosphate synthase inhibition. Denosumab works entirely outside bone matrix, which means its effects are fully reversible on discontinuation. This reversibility is clinically significant: stopping Prolia without transitioning to a bisphosphonate carries a measurable risk of rebound vertebral fracture, as documented in the FREEDOM extension trial.

Pharmacokinetics and Why Classic DDIs Are Rare

Denosumab follows non-linear target-mediated drug disposition. Peak serum concentration after a 60 mg subcutaneous dose occurs at approximately 10 days; the elimination half-life is roughly 26 days. Because denosumab is a large monoclonal antibody catabolized by the reticuloendothelial system into peptide fragments and amino acids, it is not a substrate, inhibitor, or inducer of any CYP450 enzyme, P-glycoprotein, or renal organic anion/cation transporters.

No Dose Adjustment for Renal Impairment

Unlike bisphosphonates (zoledronic acid is contraindicated when CrCl <35 mL/min), denosumab does not require renal dose adjustment. The Prolia prescribing information notes no clinically meaningful changes in pharmacokinetics in patients with severe renal impairment or those on dialysis. The trade-off: hypocalcemia risk rises sharply in patients with CrCl <30 mL/min, making calcium and vitamin D supplementation and monitoring mandatory in that population.

No Hepatic Dose Adjustment

Denosumab is not hepatically cleared. Formal pharmacokinetic studies in hepatic impairment show no clinically significant difference in exposure compared to patients with normal hepatic function.

The Practical Consequence

Because there are no CYP-based or transporter-based pharmacokinetic interactions, every meaningful DDI with denosumab is pharmacodynamic. Prescribers accustomed to checking CYP3A4 tables can skip that step, but must actively screen for agents that amplify immune suppression, worsen hypocalcemia, or have overlapping bone toxicity.

RANK-L Inhibitor Drug-Drug Interaction Table

The table below consolidates pharmacodynamic drug-drug interactions for denosumab based on the FDA-approved labeling, published pharmacovigilance data, and major clinical guidelines. Severity ratings follow a three-tier scheme: Major (avoid or manage with close monitoring), Moderate (monitor and consider dose/regimen adjustment), Minor (awareness sufficient).

Major Pharmacodynamic Interactions

| Interacting Drug / Class | Mechanism | Clinical Effect | Management | |--------------------------|-----------|-----------------|------------| | Systemic immunosuppressants (cyclosporine, tacrolimus, mycophenolate, high-dose corticosteroids) | Additive T-cell and innate immune suppression | Increased rate of serious infections (cellulitis, pneumonia, urinary tract infection); FDA label lists serious infections as a class warning | Screen for active infection before each injection; hold if serious infection is ongoing; counsel on infection signs | | Checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab) | RANK-L pathway modulates T-regulatory cell function; denosumab may alter immune checkpoint balance | Potential amplification of immune-related adverse events (irAEs) in small case series; no large RCT data | Use with caution in oncology settings; document rationale; monitor for irAE escalation | | Other antiresorptives (bisphosphonates, romosozumab, teriparatide used sequentially) | Overlapping osteoclast suppression or complex anabolic/antiresorptive sequencing effects | Additive suppression of bone turnover when bisphosphonates overlap; anabolic agents (teriparatide) show attenuated effect when given concurrently with potent antiresorptives | Avoid concurrent bisphosphonate + denosumab unless intentional transition; see AACE/ACE 2020 osteoporosis guidelines for sequencing recommendations | | Calcium-lowering agents (loop diuretics, foscarnet, cinacalcet, calcitonin in hypercalcemia) | Reduce serum calcium independently | Additive hypocalcemia, especially in vitamin D-deficient or renally impaired patients | Check corrected calcium and 25-OH vitamin D before initiating; correct deficiency first; recheck calcium at 2 and 4 weeks post-injection |

Moderate Pharmacodynamic Interactions

| Interacting Drug / Class | Mechanism | Clinical Effect | Management | |--------------------------|-----------|-----------------|------------| | Oral corticosteroids (prednisone ≥7.5 mg/day for ≥3 months) | Independent osteoclast activation via glucocorticoid-induced RANK-L upregulation | Worsens net bone loss; denosumab prescribed for this indication per label, but monitoring is distinct from general osteoporosis use | Bone density (DXA) at baseline and every 1 to 2 years; fracture risk reassessment every 12 months | | Anticonvulsants (phenytoin, carbamazepine, phenobarbital) | CYP3A4-mediated vitamin D catabolism | Lower 25-OH vitamin D levels increase hypocalcemia risk when denosumab is added | Check 25-OH vitamin D; target ≥30 ng/mL before injecting; supplement accordingly | | Proton pump inhibitors (PPIs) | Reduce calcium absorption from gut by raising gastric pH | Modest reduction in serum calcium reserve | Ensure adequate calcium intake (1,000 to 1,200 mg/day total); supplement if dietary intake is insufficient | | Systemic fluoroquinolones (high cumulative exposure) | Independent osteoclast-independent tendon/bone toxicity | Theoretical additive musculoskeletal risk; clinically unquantified | Prescribe fluoroquinolones only when necessary in patients on long-term denosumab | | Thiazolidinediones (rosiglitazone, pioglitazone) | PPARgamma activation promotes adipogenesis at the expense of osteoblastogenesis | Additive reduction in bone formation; denosumab addresses resorption side but not formation deficit | DXA monitoring; consider switching to SGLT-2 inhibitor or GLP-1 agonist if bone health is a priority |

Minor / Awareness-Level Interactions

| Interacting Drug / Class | Mechanism | Clinical Effect | Management | |--------------------------|-----------|-----------------|------------| | Calcium carbonate / vitamin D supplements | Intentional co-administration | Required; mitigates hypocalcemia | Prescribe 1,000 mg calcium + 800 IU vitamin D daily with every denosumab prescription per Endocrine Society guidelines | | Thiazide diuretics | Reduce renal calcium excretion | May mildly protect against hypocalcemia | No adjustment needed; note as a potential buffer in high-risk patients | | Aromatase inhibitors (anastrozole, letrozole, exemestane) | Estrogen suppression accelerates bone loss | Denosumab is indicated for this interaction (bone loss prevention in breast cancer); does not worsen the interaction | Standard Prolia 60 mg every 6 months is appropriate; confirm per oncology treatment plan |

Hypocalcemia: The Most Clinically Consequential Interaction

Hypocalcemia is the single most serious acute pharmacodynamic interaction risk with denosumab. The Xgeva prescribing information carries a boxed warning for hypocalcemia in patients with renal impairment. Even in the Prolia osteoporosis population, post-marketing surveillance reports show serious hypocalcemia events, including fatal cases in patients with unrecognized vitamin D deficiency.

Risk Stratification Before Each Injection

Patients at highest risk include those with:

• CrCl <30 mL/min or on dialysis
• Pre-existing hypoparathyroidism or prior thyroid/parathyroid surgery
• Malabsorption syndromes (celiac disease, short bowel syndrome, bariatric surgery)
• Active vitamin D deficiency (25-OH vitamin D <20 ng/mL)
• Concomitant cinacalcet, foscarnet, or loop diuretic use

Monitoring Protocol

The American Society for Bone and Mineral Research (ASBMR) task force recommends checking serum calcium within 2 weeks of the first injection in high-risk patients. For routine osteoporosis patients without risk factors, checking corrected calcium and 25-OH vitamin D at baseline before the first injection is sufficient per standard practice.

Supplement Prescribing

The Endocrine Society's clinical practice guideline on osteoporosis in men and the general Prolia label both specify co-prescribing at least 1,000 mg elemental calcium plus at least 400 IU vitamin D daily. Many clinicians target 800 to 1,000 IU vitamin D, especially in northern latitudes or in patients with malabsorption.

Osteonecrosis of the Jaw (ONJ) and Drug Interactions

ONJ is a class effect shared with bisphosphonates, but its risk with denosumab increases substantially at the Xgeva oncology dose (120 mg monthly) compared to Prolia (60 mg every 6 months). The American Association of Oral and Maxillofacial Surgeons (AAOMS) 2022 position paper identifies concomitant use of antiangiogenic agents as a major ONJ risk amplifier.

Antiangiogenic Combinations

Agents that increase ONJ risk when combined with denosumab at oncology doses include:

• Bevacizumab (anti-VEGF monoclonal antibody)
• Sunitinib, sorafenib, cabozantinib (multi-kinase antiangiogenics)
• Everolimus, temsirolimus (mTOR inhibitors)

The mechanism is impaired mucosal healing secondary to reduced angiogenesis. Published case series report ONJ rates of 1% to 2% with denosumab monotherapy in oncology settings, rising to 3% to 5% with concurrent antiangiogenic therapy. No prospective RCT has quantified the interaction precisely, but the signal from pharmacovigilance databases is consistent.

Pre-Treatment Dental Evaluation

All patients starting Xgeva should complete necessary invasive dental work before the first injection, as recommended by the FDA Xgeva Risk Evaluation and Mitigation Strategy (REMS). Patients on Prolia with planned oral surgery should discuss a 4-to-6-week treatment hold with their prescriber and orthopedic surgeon, though evidence for mandatory holds at the low osteoporosis dose is limited.

Infection Risk: Immunosuppressant Combinations

Denosumab suppresses osteoclast-mediated immune surveillance in bone, and RANK-L signaling plays a role in dendritic cell and T-lymphocyte function. Adding denosumab to a baseline immunosuppressant regimen increases serious infection risk beyond either agent alone.

Evidence Base

In the FREEDOM trial (N=7,808), serious adverse events of infection occurred in 4.1% of the denosumab group versus 3.4% of placebo (P<0.05 in a pre-specified analysis of specific serious infections including cellulitis and erysipelas). Most trial participants were not on concurrent immunosuppressants; real-world rates in transplant or rheumatoid arthritis populations are higher.

The 2023 American College of Rheumatology (ACR) guidelines on the prevention and treatment of glucocorticoid-induced osteoporosis conditionally recommend denosumab in patients already on methotrexate, hydroxychloroquine, or low-dose prednisone, with specific instruction to screen for infection at every visit.

Practical Prescribing Rule

Do not inject denosumab into a patient with an active serious bacterial, viral, or fungal infection. This is explicit in the Prolia and Xgeva labels. For elective procedures requiring temporary immunosuppression (for example, a pulse of IV methylprednisolone for a MS relapse), time the denosumab injection at least 2 weeks before or 2 weeks after, when practical.

Rebound Fracture Risk on Discontinuation

Stopping denosumab without transitioning to another antiresorptive produces a rapid rebound in bone turnover markers, followed by measurable bone density loss and, in some patients, multiple vertebral fractures. This is not a drug interaction in the classic sense, but it is the most dangerous prescribing error in the class.

Clinical Data

The FLEX extension and post-FREEDOM discontinuation analyses document that bone turnover markers (serum CTX-1) overshoot baseline within 3 to 6 months of the last injection and remain elevated for 12 to 18 months. Vertebral fracture incidence in the first 12 months after stopping can reach 7.1 per 100 patient-years in high-risk patients, compared to approximately 1.2 per 100 patient-years in those who transition to zoledronic acid.

Transition Protocol

The 2022 American Association of Clinical Endocrinology (AACE) Clinical Practice Guideline for Diagnosis and Treatment of Postmenopausal Osteoporosis states: "After stopping denosumab, sequential treatment with a bisphosphonate is recommended to preserve gains in BMD and prevent rebound-associated fracture risk." The guideline recommends zoledronic acid 5 mg IV as a single dose given 6 months after the last denosumab injection, or oral alendronate for patients who cannot receive IV therapy.

Prescribing Checklist Before Every Denosumab Injection

Use this checklist at each encounter (every 6 months for Prolia; monthly for Xgeva).

Pre-Injection Assessment

1. Confirm corrected serum calcium is within normal range (target ≥8.5 mg/dL).
2. Confirm 25-OH vitamin D ≥30 ng/mL, or document active supplementation.
3. Screen for active infection; do not inject if serious infection is present.
4. Review concomitant medications for: loop diuretics, cinacalcet, foscarnet, new immunosuppressants, antiangiogenics.
5. Ask about new dental symptoms or planned oral surgery.
6. Assess CrCl; if CrCl <30 mL/min, check calcium at 2 and 4 weeks post-injection.

Post-Injection Counseling Points

• Calcium plus vitamin D supplementation daily (do not skip doses).
• Report jaw pain, thigh pain, or unusual femoral pain promptly.
• Do not stop denosumab injections without contacting the prescriber; stopping without a transition plan carries fracture risk.
• Next injection must occur on schedule; a delay of more than 4 weeks beyond the 6-month interval significantly erodes bone density gains.

Key Clinical Trial Data Supporting the Class

Three trials define the evidence base that prescribers cite most often.

FREEDOM Trial (Prolia, Osteoporosis)

The FREEDOM trial (N=7,808) randomized postmenopausal women with osteoporosis (T-score between -2.5 and -4.0 at lumbar spine or total hip) to denosumab 60 mg every 6 months versus placebo. At 36 months, new vertebral fractures occurred in 2.3% of denosumab patients versus 7.2% of placebo (68% relative risk reduction; P<0.001). Hip fracture incidence was 0.7% versus 1.2% (40% relative risk reduction; P<0.04).

HALT Trial (Prolia, Hormone Ablation)

The HALT trial (N=1,468) enrolled men receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. Denosumab 60 mg every 6 months increased lumbar spine BMD by 5.6% versus a loss of 1.0% with placebo at 24 months (P<0.001), with a significant reduction in new vertebral fracture incidence (1.5% vs. 3.9%; P=0.006).

20050103 Trial (Xgeva, Bone Metastases)

The key Xgeva versus zoledronic acid trial (N=1,776) in patients with bone metastases from solid tumors showed denosumab was superior to zoledronic acid in delaying time to first skeletal-related event (SRE): median 27.7 months versus 19.4 months (hazard ratio 0.82; 95% CI 0.71 to 0.95; P<0.001 for non-inferiority, P=0.008 for superiority). Hypocalcemia was more common with denosumab (9.6% vs. 5.0%), reinforcing the DDI monitoring requirements above.